Industry
Shaperon
Total Trials
6
Recruiting
0
Active
1
Completed
4
Success Rate
100.0%+13% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
Failure Rate
0.0%
0 terminated/withdrawn out of 6 trials
Success Rate
100.0%
+13.5% vs industry average
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
25%
1 of 4 completed trials have results
Key Signals
1 with results
Enrollment Performance
Analytics
Phase 2
4(66.7%)
Phase 1
2(33.3%)
6Total
Phase 2(4)
Phase 1(2)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (6)
Showing 6 of 6 trials
NCT06024499Phase 2Active Not Recruiting
Phase 2 Trial of HY209gel in Atopic Dermatitis Patients
Role: lead
NCT05352347Phase 2Unknown
Phase 2b/3 Trial of NuSepin® in COVID-19 Pneumonia Patients
Role: lead
NCT04565379Phase 2Completed
Clinical Trial to Investigate the Efficacy and Safety of NuSepin® in COVID-19 Pneumonia Patients
Role: lead
NCT04530643Phase 2Completed
A Phase II Study of HY209 Gel for Atopic Dermatitis Patients (Shaperon)
Role: lead
NCT03492398Phase 1Completed
A Phase I Study of HY209 Gel in Healthy Male Volunteers for Atopic Dermatitis
Role: lead
NCT04255979Phase 1Completed
A Study of HY209 in Healthy Male Volunteers for Sepsis
Role: lead
All 6 trials loaded